Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Doxycycline

FDA-approved product (for suspension, oral), marketed as Doxychel, Doxycycline, Monodox and 15 more.

Registered studies
50+
Lab records
7
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Doxycycline
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Anthrax infection
  • Bacterial disease
  • Brucellosis
  • Gonorrhea
  • Infection
  • Malaria
  • Ornithosis
  • Periodontitis
  • Pneumonia
  • Rosacea
  • Spotted fever
  • Tularemia
  • Typhus
  • Vibrio infectious disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives and antiseptics for local oral treatment; Tetracyclines
FDA pharmacologic class
Tetracycline-class Drug FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01AA02; FDA class Tetracycline-class Drug

Repurposing investigation

Doxycycline is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA80.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli88.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae64.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
  • E. coli: measured active in 4 of 6 lab records
Open Doxycycline in ChEMBL Registered studies below
Show the 7 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Doxycycline with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Multicentre Study Evaluating the Efficacy of a 7-day Course of Doxycycline for the Treatment of Asymptomatic Anal Lymphogranuloma Venereum.

    NCT07767422 · start 2026-09

    Registered record
    Registry ID
    NCT07767422
    Conditions
    Lymphogranuloma Venereum; no Anorectal Symptoms; Doxycycline
    Interventions
    Doxycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2027-11
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphogranuloma Venereum; no Anorectal Symptoms; Doxycycline
    InterventionDoxycline
    PhasePhase 2
    Registry statusNot yet recruiting

  • Fecal Molecular Susceptibility-guided Hp First-line Therapy

    NCT07405684 · start 2026-02-28

    Registered record
    Registry ID
    NCT07405684
    Conditions
    HELICOBACTER PYLORI INFECTIONS
    Interventions
    7-day fecal molecular susceptibility-guided therapy; 14-day fecal molecular susceptibility-guided therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-02-28
    Completion
    2028-12-31
    Enrolment
    544

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHELICOBACTER PYLORI INFECTIONS
    Intervention7-day fecal molecular susceptibility-guided therapy; 14-day fecal molecular susceptibility-guided therapy
    PhasePhase 4
    Registry statusNot yet recruiting

  • The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea

    NCT07343635 · start 2026-02-01

    Registered record
    Registry ID
    NCT07343635
    Conditions
    Erythematotelangiectatic Rosacea
    Interventions
    Doxycycline; Hydroxychloroquine; Tofacitinib; Anti-inflammatory Treatment (Hirudoid Introduction Followed by Yellow Light Therapy)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-02-01
    Completion
    2027-07-01
    Enrolment
    186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErythematotelangiectatic Rosacea
    InterventionDoxycycline; Hydroxychloroquine; Tofacitinib; Anti-inflammatory Treatment (Hirudoid Introduction Followed by Yellow Light Therapy)
    PhaseNot applicable
    Registry statusRecruiting

  • Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP

    NCT06414408 · start 2024-10-18

    Registered record
    Registry ID
    NCT06414408
    Conditions
    Sexually Transmitted Diseases, Bacterial
    Interventions
    Doxycycline Pill
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2024-10-18
    Completion
    2028-12-01
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSexually Transmitted Diseases, Bacterial
    InterventionDoxycycline Pill
    PhaseEarly phase 1
    Registry statusRecruiting

  • Efficacy of Local Doxycycline Gel Delivery Versus Doxycycline Nanoparticles Prepared Gel in The Treatment of Stage II Periodontitis

    NCT06994455 · start 2024-06-02

    Registered record
    Registry ID
    NCT06994455
    Conditions
    Periodontitis
    Interventions
    scaling and root planing along with antibiotic intervention; scaling and root planing along with antibiotic intervention; scaling and root planing
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-06-02
    Completion
    2025-09
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeriodontitis
    Interventionscaling and root planing along with antibiotic intervention; scaling and root planing along with antibiotic intervention; scaling and root planing
    PhaseNot applicable
    Registry statusUnknown

  • Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)

    NCT07488949 · start 2024-04-09

    Registered record
    Registry ID
    NCT07488949
    Conditions
    Chronic Endometritis
    Interventions
    Doxycycline combined with Medroxyprogesterone; Doxycycline combined with placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-04-09
    Completion
    2031-12-31
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Endometritis
    InterventionDoxycycline combined with Medroxyprogesterone; Doxycycline combined with placebo
    PhaseNot applicable
    Registry statusRecruiting

  • Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

    NCT06120140 · start 2024-02-16

    Registered record
    Registry ID
    NCT06120140
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Amivantamab IV; Amivantamab SC; Lazertinib; Doxycycline; Minocycline; Clindamycin; Chlorhexidine; Noncomedogenic skin moisturizer; Ruxolitinib; Tacrolimus; Zinc gluconate; Propranolol; Timolol; Clobetasol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-02-16
    Completion
    2030-06-30
    Enrolment
    305

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionAmivantamab IV; Amivantamab SC; Lazertinib; Doxycycline +10 more
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study of Doxycycline to Treat Chlamydial Infection

    NCT05840159 · start 2024-01-19

    Registered record
    Registry ID
    NCT05840159
    Conditions
    Chlamydial Infection
    Interventions
    Doxycycline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-01-19
    Completion
    2026-02-12
    Enrolment
    526

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChlamydial Infection
    InterventionDoxycycline; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Omega-3 Pufa and Aspirin as Adjunctive Therapy in Treatment of Smoker Patients With Stage Iii Periodontitis

    NCT07385300 · start 2023-08-20

    Registered record
    Registry ID
    NCT07385300
    Conditions
    Periodontitis; Diabete Mellitus
    Interventions
    Omega-3 PUFA and Aspirin as adjunctive therapy to (SRP); Omega-3 PUFA and Aspirin and doxycycline as adjunctive therapy to (SRP); scaling and root planning (SRP)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-08-20
    Completion
    2024-08-22
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeriodontitis; Diabete Mellitus
    InterventionOmega-3 PUFA and Aspirin as adjunctive therapy to (SRP); Omega-3 PUFA and Aspirin and doxycycline as adjunctive therapy to (SRP); scaling and root planning (SRP)
    PhaseNot applicable
    Registry statusCompleted

  • Ocular Rosacea Biome Study

    NCT05296837 · start 2023-06-22

    Registered record
    Registry ID
    NCT05296837
    Conditions
    Ocular Rosacea; Antimicrobial Resistance
    Interventions
    Doxycycline 40 MG ( 20mg twice daily); Doxycycline 200 MG ( 100 mg twice daily); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-06-22
    Completion
    2025-07-14
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Rosacea; Antimicrobial Resistance
    InterventionDoxycycline 40 MG ( 20mg twice daily); Doxycycline 200 MG ( 100 mg twice daily); Placebo
    PhasePhase 4
    Registry statusCompleted

  • Doxycycline Intervention for Bacterial STI ChemoprOphylaxis (DISCO)

    NCT04762134 · start 2023-06-02

    Registered record
    Registry ID
    NCT04762134
    Conditions
    Bacterial Sexually Transmitted Diseases
    Interventions
    Doxycycline Hyclate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-06-02
    Completion
    2027-06-30
    Enrolment
    560

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Sexually Transmitted Diseases
    InterventionDoxycycline Hyclate
    PhaseNot applicable
    Registry statusRecruiting

  • Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension

    NCT05678621 · start 2022-11-30

    Registered record
    Registry ID
    NCT05678621
    Conditions
    Haematological Malignancy; Hypogammaglobulinemia
    Interventions
    trimethoprim-sulfamethoxazole (co-trimoxazole); amoxycillin/clavulanic acid and ciprofloxacin; Immunoglobulins
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2022-11-30
    Completion
    2027-04
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHaematological Malignancy; Hypogammaglobulinemia
    Interventiontrimethoprim-sulfamethoxazole (co-trimoxazole); amoxycillin/clavulanic acid and ciprofloxacin; Immunoglobulins
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Efficacy of Azithromycin Plus Doxycycline Versus Doxycycline Plus Placebo in Patients With Rocky Mountain Spotted Fever

    NCT05398055 · start 2022-05-12

    Registered record
    Registry ID
    NCT05398055
    Conditions
    Rocky Mountain Spotted Fever
    Interventions
    Azithromycin + Doxycycline; Placebo + Doxycycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2022-05-12
    Completion
    2025-12-31
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRocky Mountain Spotted Fever
    InterventionAzithromycin + Doxycycline; Placebo + Doxycycline
    PhasePhase 3
    Registry statusUnknown

  • Helicobacter Pylori Eradication and Follow-up

    NCT05061732 · start 2021-09-30

    Registered record
    Registry ID
    NCT05061732
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Rabeprazole; Bismuth potassium citrate; Metronidazole; Clarithromycin; Levofloxacin; Amoxicillin; Metronidazole; Doxycycline; Tetracycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-09-30
    Completion
    2026-06-30
    Enrolment
    4,447

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionRabeprazole; Bismuth potassium citrate; Metronidazole; Clarithromycin +5 more
    PhasePhase 4
    Registry statusUnknown

  • Doxycycline for Elbow Tendinopathy

    NCT04686799 · start 2020-12-03

    Registered record
    Registry ID
    NCT04686799
    Conditions
    Lateral Epicondylitis; Lateral Epicondylitis, Left Elbow; Lateral Epicondylitis, Right Elbow; Lateral Epicondylitis, Unspecified Elbow; Lateral Epicondylitis (Tennis Elbow) Bilateral; Medial Epicondylitis; Medial Epicondylitis, Right Elbow; Medial Epicondylitis, Left Elbow
    Interventions
    Doxycycline Hyclate 20 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-12-03
    Completion
    2025-10-09
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLateral Epicondylitis; Lateral Epicondylitis, Left Elbow; Lateral Epicondylitis, Right Elbow; Lateral Epicondylitis, Unspecified Elbow +4 more
    InterventionDoxycycline Hyclate 20 MG
    PhasePhase 1
    Registry statusCompleted